Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 4
2001 9
2002 32
2003 50
2004 44
2005 37
2006 52
2007 54
2008 49
2009 54
2010 37
2011 39
2012 34
2013 28
2014 35
2015 21
2016 22
2017 17
2018 14
2019 10
2020 8
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

592 results
Results by year
Filters applied: . Clear all
Page 1
Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA).
Mukherjee S, Ayanambakkam A, Ibrahimi S, Schmidt S, Charkrabarty JH, Khawandanah M. Mukherjee S, et al. Hematol Oncol Stem Cell Ther. 2018 Sep;11(3):187-188. doi: 10.1016/j.hemonc.2017.12.004. Epub 2018 Feb 1. Hematol Oncol Stem Cell Ther. 2018. PMID: 29406240 Free article. Review.
Ibritumomab Tiuxetan (Zevalin) is an anti CD-20 murine monoclonal antibody linked to the radio-isotope 90-yttrium (90Y) by the chelator Tiuxetan. ...There is a concern for development of hypersensitivity reactions with Ibritumomab, especially in patien
Ibritumomab Tiuxetan (Zevalin) is an anti CD-20 murine monoclonal antibody linked to the radio-isotope 90-yttrium (90Y) by the
Zevalin() (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?
Rizzieri D. Rizzieri D. Crit Rev Oncol Hematol. 2016 Sep;105:5-17. doi: 10.1016/j.critrevonc.2016.07.008. Epub 2016 Jul 16. Crit Rev Oncol Hematol. 2016. PMID: 27497027 Review.
Despite the efficacy and acceptable safety profile of ibritumomab tiuxetan, utilization has not been broadly adopted in practice due to a number of factors. This manuscript will review the literature available for ibritumomab tiuxetan, including severa …
Despite the efficacy and acceptable safety profile of ibritumomab tiuxetan, utilization has not been broadly adopted in practi …
Ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Johnston PB, Bondly C, Micallef IN. Johnston PB, et al. Expert Rev Anticancer Ther. 2006 Jun;6(6):861-9. doi: 10.1586/14737140.6.6.861. Expert Rev Anticancer Ther. 2006. PMID: 16761929 Review.
Targeted radiation therapy, or radioimmunotherapy, has been an important recent advancement in the treatment of patients with B-cell non-Hodgkin's lymphoma (NHL). 90Y ibritumomab tiuxetan comprises the murine monoclonal antibody ibritumomab, the linker chelat …
Targeted radiation therapy, or radioimmunotherapy, has been an important recent advancement in the treatment of patients with B-cell non-Hod …
Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
Witzig TE. Witzig TE. Drugs Today (Barc). 2004 Feb;40(2):111-9. doi: 10.1358/dot.2004.40.2.799423. Drugs Today (Barc). 2004. PMID: 15045033 Review.
Tiuxetan is an MX-DTPA chelator that is linked to ibritumomab to form ibritumomab tiuxetan. ...In the first trial, cold ibritumomab was used prior to ibritumomab tiuxetan; the second trial used the human chimeric antibody rituximab
Tiuxetan is an MX-DTPA chelator that is linked to ibritumomab to form ibritumomab tiuxetan. ...In the first tria
Yttrium 90 Ibritumomab Tiuxetan.
[No authors listed] [No authors listed] 2020 Aug 17. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Drugs and Lactation Database (LactMed). 2006–. PMID: 29999770 Free Books & Documents. Review.
Information in this record refers to the use of yttrium 90 ibritumomab tiuxetan as a therapeutic agent. No information is available on the use of yttrium 90 ibritumomab tiuxetan during breastfeeding. ...
Information in this record refers to the use of yttrium 90 ibritumomab tiuxetan as a therapeutic agent. No information is avai …
Indium 111 Ibritumomab Tiuxetan.
[No authors listed] [No authors listed] 2020 Aug 17. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Drugs and Lactation Database (LactMed). 2006–. PMID: 29999760 Free Books & Documents. Review.
Information in this record refers to the use of indium 111 ibritumomab tiuxetan as a diagnostic agent. No information is available on the use of indium 111 ibritumomab tiuxetan during breastfeeding. ...
Information in this record refers to the use of indium 111 ibritumomab tiuxetan as a diagnostic agent. No information is avail …
Rituximab-PECC induction followed by (90) Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.
Lugtenburg PJ, Zijlstra JM, Doorduijn JK, Böhmer LH, Hoogendoorn M, Berenschot HW, Beeker A, van der Burg-de Graauw NC, Schouten HC, Bilgin YM, Kersten MJ, Koene HR, Herbers AHE, de Jong D, Hijmering N, Lam KH, Chiţu D, Brouwer RE, van Imhoff GW; Dutch HOVON group. Lugtenburg PJ, et al. Br J Haematol. 2019 Nov;187(3):347-355. doi: 10.1111/bjh.16087. Epub 2019 Jul 10. Br J Haematol. 2019. PMID: 31290569 Clinical Trial.
Twenty-nine of 31 responsive patients proceeded to (90) Y-ibritumomab tiuxetan. Five out of 15 partial remission patients converted to complete remission after (90) Y-ibritumomab tiuxetan. ...Consolidation with (90) Y-ibritumomab tiuxetan
Twenty-nine of 31 responsive patients proceeded to (90) Y-ibritumomab tiuxetan. Five out of 15 partial remission patients conv …
90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr.
Mondello P, Cuzzocrea S, Navarra M, Mian M. Mondello P, et al. Oncotarget. 2016 Feb 16;7(7):7597-609. doi: 10.18632/oncotarget.6531. Oncotarget. 2016. PMID: 26657116 Free PMC article. Review.
Y-ibritumomab tiuxetan (90Y-IT) combines the benefits of a monoclonal antibody with the efficacy of radiation in the treatment of B-cell non-Hodgkin lymphoma (NHL), a remarkably radiosensitive hematologic malignancy. 90Y-IT activity has been well established in the …
Y-ibritumomab tiuxetan (90Y-IT) combines the benefits of a monoclonal antibody with the efficacy of radiation in the treatment …
Yttrium 90 ibritumomab tiuxetan in lymphoma.
Cheung MC, Haynes AE, Stevens A, Meyer RM, Imrie K; Members of the Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-Based Care. Cheung MC, et al. Leuk Lymphoma. 2006 Jun;47(6):967-77. doi: 10.1080/10428190600572582. Leuk Lymphoma. 2006. PMID: 16840185 Review.
A total of twenty trials investigating the use of 90Y-ibritumomab tiuxetan for the treatment of adult patients with NHL were identified. ...However, in rituximab-naive patients with relapsed or refractory indolent or transformed NHL, the higher response rate seen wi …
A total of twenty trials investigating the use of 90Y-ibritumomab tiuxetan for the treatment of adult patients with NHL were i …
Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice.
Hagenbeek A. Hagenbeek A. Leuk Lymphoma. 2003;44 Suppl 4:S37-47. doi: 10.1080/10428190310001616944. Leuk Lymphoma. 2003. PMID: 15154741 Review.
In addition, a major phase III randomized trial directly compared 90Y-ibritumomab tiuxetan with the unlabeled anti-CD20 MAb rituximab. Results from the randomized trial demonstrated that OR and CR rates were significantly higher with 90Y-ibritumomab tiuxet
In addition, a major phase III randomized trial directly compared 90Y-ibritumomab tiuxetan with the unlabeled anti-CD20 MAb ri …
592 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page